New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
15:16 EDTMYLMylan announces Fortamet settlement agreement
Mylan announced that its subsidiary, Mylan Pharmaceuticals, has entered into a settlement agreement with Shionogi and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic version of Shionogi's Fortamet, and is indicated as an adjunct to diet and exercise to lower blood glucose. Under the terms of the settlement agreement, Mylan may launch a generic version of Fortamet on August 1, or earlier under certain conditions. Pursuant to the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
19:48 EDTMYLMylan 35M share Secondary priced at $58.35
Subscribe for More Information
09:50 EDTMYLMylan launches generic Exforge tablets in U.S.
Subscribe for More Information
March 30, 2015
13:01 EDTMYLOptions with increasing volume
Subscribe for More Information
10:46 EDTMYLOptions with increasing implied volatility
Subscribe for More Information
10:24 EDTMYLMylan volatility up after filing to sell 35M shares for Abbott Laboratories
Subscribe for More Information
09:27 EDTMYLOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTMYLTeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTMYLMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
06:34 EDTMYLMylan files to sell 35M shares of stock for Abbott Laboratories subsidiaries
Subscribe for More Information
March 27, 2015
07:45 EDTMYLFDA to hold a public meeting
Subscribe for More Information
07:25 EDTMYLTeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use